Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01520038 · ClinicalTrials.gov registry record · Phase 1
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01520038 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2 participants.
The verdict
NCT01520038, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Invasive urothelial bladder cancer is a common malignancy causing 14,000 deaths annually in the United States. The primary objective of the feasibility/Phase I portion of the study is to establish the feasibility and safety of proton and the safety of IMRT for patients with pure or mixed variant urothelial carcinoma.
Interventions
- RADIATION IMRT
- RADIATION Proton therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01520038
The ClinicalTrials.gov registry entry for NCT01520038 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMRT is the first listed.
NCT01520038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01520038 about?
NCT01520038 is a clinical study titled "Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer". Invasive urothelial bladder cancer is a common malignancy causing 14,000 deaths annually in the United States. The primary objective of the feasibility/Phase I portion of the study is to establish the feasibility and safety of proton and the safety of IMRT for patients with pure or mixed variant uro...
What is the current status of trial NCT01520038?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2012-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01520038?
The interventions under investigation include: IMRT (RADIATION), Proton therapy (RADIATION).
Who is sponsoring clinical trial NCT01520038?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.